LAPIX Therapeutics has secured a US patent for LPX-TI641, its orally administered Tim3/4 agonist for regulatory T cell (Treg) expansion for the treatment of autoimmune diseases.

Patent number 11,648,225 has been issued by the US patent and trademark office.

LPX-TI641 restores the Treg population using an antigen-agnostic method to treat autoimmune diseases.

It is being developed for neuro-autoimmune indications including multiple sclerosis (MS) with an aim to widen its usage to other indications.

The therapy’s Phase I trial is anticipated to begin enrolment in July this year.

Autoimmune diseases including MS are characterised by loss of self-tolerance [the ability of the immune system to recognise self-produced antigens as a non-threat while appropriately mounting a response to foreign substances]. They are mostly related to the downregulation of functional regulatory T and B-cells (Treg and Breg) as well as the upregulation of autoreactive pathogenic T helper type 17 and type 1 T cells (Th).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

LPX-TI641 enables the adaptive immune system to restore self-tolerance by reinstating the autoimmune diseases-related Treg/pathogenic T-cell imbalance, without impacting the innate immune system and inducing lymphocytopenia or leukopenia.

LAPIX Therapeutics CEO and co-founder Anas Fathallah stated: “Treating autoimmune diseases by re-establishing self-tolerance in an antigen-agnostic manner with an orally administered therapeutic is a new approach that will unleash the power of immune tolerance while breaking free of the limitations of yesteryear’s antigen-specific immune tolerance approaches.

“This is very promising for the treatment of autoimmune diseases in general and MS in particular.”